MedTrace Logo

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

NCT04430933 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2021-08-18

No results posted yet for this study

Summary

This research study is studying an investigational drug, NC318, as a possible treatment for subjects with advanced or metastatic non-small cell lung cancer in combination with chemotherapy

Conditions

Interventions

DRUG

NC318

NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle

DRUG

Pemetrexed/Carboplatin

Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle

DRUG

Nab paclitaxel/Carboplatin

Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle

DRUG

Docetaxel

Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle

Sponsors & Collaborators

  • NextCure, Inc.

    lead INDUSTRY

Principal Investigators

  • Sol Langermann, PhD · NextCure, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-06
Primary Completion
2022-06-30
Completion
2022-10-30
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04430933 on ClinicalTrials.gov